DOCSLIB.ORG

Mechanism of Bilirubin Diglucuronide Formation in Intact Rats: BILIRUBIN

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanism of Bilirubin Diglucuronide Formation in Intact Rats: BILIRUBIN Mechanism of Bilirubin Diglucuronide Formation in Intact Rats BILIRUBIN DIGLUCURONIDE FORMATION IN VIVO NORBERT BLANCKAERT, JOHN GOLLAN, and RUDI SCHMID, Department of Medicine and Liver Center, University of California School of Medicine, San Francisco, California 94143; Laboratory of Hepatology, Department of Medical Research, University of Leuven, B-3000, Leuven, Belgium A B S T R A C T Although it is well established that bili- ['4C]monoglucuronide, no transfer or exchange of the rubin monoglucuronide is formed in the liver from bili- ['4C]glucuronosyl group between injected and en- rubin by a microsomal bilirubin uridine diphosphate dogenously produced bilirubin monoglucuronide (UDP)-glucuronosyltransferase, the subcellular site of could be detected in the excreted bilirubin diglucuron- conversion of monoglucuronide to diglucuronide and ide. Third, in homozygous Gunn rats, injected "4C- the molecular mechanism involved in diglucuronide labeled or unlabeled bilirubin mono- or digluc- synthesis have not been identified. Based on in vitro uronides were excreted in bile unchanged (except that studies, it has been proposed that two fundamentally diglucuronide was hydrolyzed to a minor degree). This different enzyme systems may be involved in di- indicates that Gunn rats, which lack bilirubin UDP- glucuronide synthesis in rat liver: (a) a microsomal glucuronosyltransferase activity, are unable to convert UDP-glucuronosyltransferase system requiring UDP- injected monoglucuronide to diglucuronide. Collec- glucuronic acid as sugar donor or (b) a transglucuroni- tively, these findings establish that a transglucuronida- dation mechanism that involves transfer of a glucurono- tion mechanism is not operational in vivo and support syl residue from one monoglucuronide molecule to the concept that bilirubin diglucuronide is formed by another, catalyzed by a liver plasma membrane en- a microsomal UDP-glucuronosyltransferase system. zyme. To clarify the mechanism by which bilirubin monoglucuronide is converted in vivo to diglucuron- INTRODUCTION ide, three different experimental approaches were used. First, normal rats were injected with either equal Bilirubin,' the principal degradation product of amounts of bilirubin-IIIa ['4C]monoglucuronide and heme in mammals (1), is excreted in bile largely in unlabeled bilirubin-XIIIa monoglucuronide, or bili- the form of polar derivatives in which one or both rubin-XIIIa ['4C]monoglucuronide and unlabeled bili- propionic acid ,8-substituents of the pigment are esteri- rubin-IIIa monoglucuronide. Analysis of radiolabeled fied with a sugar, predominantly glucuronic acid (2, 3). diglucuronide excreted in bile showed that ["4C]- This conjugation is thought to disrupt the multiple in- glucuronosyl residues were not transferred between tramolecular hydrogen bonds responsible for the non- monoglucuronide molecules. Second, in normal rats in- polar character of bilirubin and thereby renders the fused intravenously with dual-labeled [3H]bilirubin pigment excretable in bile (4). It is well established that formation of bilirubin monoglucuronide (BMG) is catalyzed by microsomal uridine diphosphate (UDP)- This work was presented in part at the 79th Annual Meeting glucuronosyltransferase [UDP-glucuronate /3-glucuron- of the American Gastroenterology Association 22-25 May osyltransferase (acceptor unspecific), EC 2.4.1.17], 1978. Gastroenterology. 74: 1166. (Abstr.) with UDP-glucuronic acid (UDPGlcUA) serving as Dr. Blanckaert is an Appointed Investigator of the Belgian National Research Council and a grantee of a North Atlantic sugar donor (5). It remained unexplained, however, Treaty Organization research fellowship and Senior Ful- bright-Hays scholarship. Address reprint requests to Dr. I Abbreviations used in this paper: bilirubin, bilirubin-IXa; Blanckaert in Califomia. BDG,bilirubin diglucuronide; BMG, bilirubin monoglucuronide; Received for publication 24 August 1979 and in revised TLC, thin-layer chromatography; UDP, uridine diphosphate; form 7 February 1980. UDPGlcUA, uridine diphosphate glucuronic acid. 1332 J. Clin. Invest. © The American Society for-Clinical Investigation, Inc. * 0021-9738/80/06/1332/11 $1.00 Volume 65 June 1980 1332-1342 whv on incubation of liver homogenate or microsomiies et al. (11) reported formation of BDG from administered frolm humans, rats, dogs, and cats with UDPGlcUA, BMG in amounts comparable to those in normal rats. the reaction product was largely BMG (6), while in The present study was undertaken to clarify the these species bile contains predominantly bilirubin mechanism of BDG formation in vivo. Experiments diglucuronide (BDG) (2, 3, 7-9). Because of this ap- were devised to examine whether BDG is synthesized parent inconsistenicy between the findings in vivo and in vivo in normal rats by transglucuronidation of BMG, in vitro, it has been postulated that conversion of B.MG and whether homozygous Gunn rats can convert ad- to BDG is catalyzed by a separate enzyme that differs ministered BMIG to BDG. fromii bilirubin UDP-glucuronosyltransferase. Recenitly, it has been reported that in rat liver, synthesis of BDG Experimiental approach f'rom BMG is catalyzed by BMIG glucuronosyltrans- f'erase, an enzyme which is distinct from microsomiial In intact normal rats we carried out two different UDP-glucuronosyltransferase in its reaction mechanismii types of' experiments designed to detect transfer of and subcellular location (10). This enzyme is believed glucuronosyl residues betweeni BMG molecules (trans- to convert BMG to BDG by transf'er of' a glucuronisyl glucuronidationi). The first approach (series I) was group from one BMG molecule to aniother, whereby based on the dissymmiletry of bilirubin, wlhich is due to 1 mol of bilirubini aind 1 mol of BDG are f'ormed f'rom the different sequence of' the mnethyl and vinyl 8-sub- 2 mol of BMG. This transglucuroniidlationi reaction does stitueints oIn the outer pyrrolinoine rings. The molecule not require UDPGlcUA as sugar dconor, aind the enzymile thus contaiins two dissimilar (lipyrivlm-ietheines, which involved exhibits highest specific activity in the plasma we shall designate as A (with endovinyl side chain) and membrane fraction. The reported reactioni rate of'BMG B (with exovinyl side chaini), respectively. For con- glucturonosyltransf'erase in rat aind humain liver f:ar venience the comiiplete molecule is denoted as A-B (Fig. exceeds that of' microsomal bilirubin UDP-glucuronio- 1). Bilirubin monoglucuronide theref'ore exists in syltransf'erase. An unimilpaired rate of' conversion of' two isomeric f'orms that diff'er by the attachment of BMG to BDG in vitro hals been observed in liver prep- the sugar mnoiety to either the A or the B dipyrmylmethene.2 arations f'rom patients with Crigler-Naijjir disease type 1 Both isomers are formed when liver homnogenate or and f'rom homozygous Gunn rats (11), 1)oth of whiclh microsomiies are inculbated with bilinibin and UDPGlcUA lack detectable hepatic bilirubin UDP-glucturonosvl- (17, 19), anl 1)oth have been idlentified in rat bile (8, 9). tranisf'erase activity. For unknown reasons, the moinoglucuronide con-jugated Several well-established observations in humansi anid in A uisually predominiiates (9, 17, 19). rats in vivo have indlicated that, in the presence of' If'BDG were f'ormed by a tranisglucuronidatioin mechi- either a high hepatic bilirubin conicentration or reduce(d anisin, 14C-labeled glucuroniosyl groups f'or exacmple, mnicrosomial bilirtubin UDP-glucturoniosyltransferase ac- attached exclusively to dipvrrvlmlethene A of' injected tivity, the liver preferenitially formns BMG (9, 12-16). BMG would be tranisf'erredl to both the A and B halves Theref'ore, we examinied the microsomn-al UDP-gltuc- of' other BCIG molecules. However, since the two iso- tironosyltranisf'erase system of'rat liver to see whether, inieric bilirubiin miioinoglucuroinides have Inot beenI undi(ler the standard assay conditionis, the pref'erential isolated or syinthesized individually, BMG with a radio- formncationi of BMGI is related to the uniiphysiologicallv labeled conijugatinig group attaclhed exclusively to ei- high bilirubfin substrate coincenitrationis used. 'We fotund ther the A or B dipvrrylmethene is not available. We that wheni the pigmnenit substrate conicentrationi in the tlheref'ore used as mnodel comiipounds the radiolabeled incubation Imlediumiil was substantially (lecreased, liver monoglucuroinides of' the symmiiiietrical bilirubin-IIIa mierosomiies formncapproximately e(lqtal amiiounts of'B\IG aind -XI11a (Fig. 1). Sinice each of'these molecules conl- anll BDG firom bilirtubin andl readily convert addled taiins either two B or two A dlipvrrylmnethenes, the ra- B.MG to BDG (17). Both reactions are critically depend- dliolabele(l glucuronosyl group is attached solely to B enit on UDPGlcUA, as neither liver hlomogenate nor in the Illa anid to A in the XIIIa isomiier. Physiologi- mnicrosomiies conivert bilirubin or BNIG to BDG in the cally, the bilirubin-IIIa anid -XIIIa isomers and their absence of'addledl UDPGlcUA. Mloreover, synthesis in monioglucuroniides behave simiiilatrly to the correspond- vitro of' BDG fromn BMG was found to be deficienit ini ing IXa isomiiers (Restults). homnozygouis Gunnli rats. These findings in vitro stug- Rats providedl witlh an externlcal bile fistultla were ini- gestedl that formation of both B.NIG aindl BDG is catalyzedl jecte(l intravenoisvly with at miiixture of' equial aImlounlts by a microsomiial U DP-glucuroniosyltransferase systemii, of' bilirtubin-XII11a
Load more

Recommended publications
  • Hyperbilirubinemia
    Porphyrins Porphyrins (Porphins) are cyclic tetrapyrol compounds formed by the linkage )). of four pyrrole rings through methenyl bridges (( HC In the reduced porphyrins (Porphyrinogens) the linkage of four pyrrole rings (tetrapyrol) through methylene bridges (( CH2 )) The characteristic property of porphyrins is the formation of complexes with the metal ion bound to nitrogen atoms of the pyrrole rings. e.g. Heme (iron porphyrin). Proteins which contain heme ((hemoproteins)) are widely distributed e.g. Hemoglobin, Myoglobin, Cytochromes, Catalase & Tryptophan pyrrolase. Natural porphyrins have substituent side chains on the eight hydrogen atoms numbered on the pyrrole rings. These side chains are: CH 1-Methyl-group (M)… (( 3 )) 2-Acetate-group (A)… (( CH2COOH )) 3-Propionate-group (P)… (( CH2CH2COOH )) 4-Vinyl-group (V)… (( CH CH2 )) Porphyrins with asymmetric arrangement of the side chains are classified as type III porphyrins while those with symmetric arrangement of the side chains are classified as type I porphyrins. Only types I & III are present in nature & type III series is more important because it includes heme. 1 Heme Biosynthesis Heme biosynthesis occurs through the following steps: 1-The starting reaction is the condensation between succinyl-CoA ((derived from citric acid cycle in the mitochondria)) & glycine, this reaction is a rate limiting reaction in the hepatic heme synthesis, it occurs in the mitochondria & is catalyzed by ALA synthase (Aminolevulinate synthase) enzyme in the presence of pyridoxal phosphate as a cofactor. The product of this reaction is α-amino-β-ketoadipate which is rapidly decarboxylated to form δ-aminolevulinate (ALA). 2-In the cytoplasm condensation reaction between two molecules of ALA is catalyzed by ALA dehydratase enzyme to form two molecules of water & one 2 molecule of porphobilinogen (PBG) which is a precursor of pyrrole.
    [Show full text]
  • Porphyrins & Bile Pigments
    Bio. 2. ASPU. Lectu.6. Prof. Dr. F. ALQuobaili Porphyrins & Bile Pigments • Biomedical Importance These topics are closely related, because heme is synthesized from porphyrins and iron, and the products of degradation of heme are the bile pigments and iron. Knowledge of the biochemistry of the porphyrins and of heme is basic to understanding the varied functions of hemoproteins in the body. The porphyrias are a group of diseases caused by abnormalities in the pathway of biosynthesis of the various porphyrins. A much more prevalent clinical condition is jaundice, due to elevation of bilirubin in the plasma, due to overproduction of bilirubin or to failure of its excretion and is seen in numerous diseases ranging from hemolytic anemias to viral hepatitis and to cancer of the pancreas. • Metalloporphyrins & Hemoproteins Are Important in Nature Porphyrins are cyclic compounds formed by the linkage of four pyrrole rings through methyne (==HC—) bridges. A characteristic property of the porphyrins is the formation of complexes with metal ions bound to the nitrogen atom of the pyrrole rings. Examples are the iron porphyrins such as heme of hemoglobin and the magnesium‐containing porphyrin chlorophyll, the photosynthetic pigment of plants. • Natural Porphyrins Have Substituent Side Chains on the Porphin Nucleus The porphyrins found in nature are compounds in which various side chains are substituted for the eight hydrogen atoms numbered in the porphyrin nucleus. As a simple means of showing these substitutions, Fischer proposed a shorthand formula in which the methyne bridges are omitted and a porphyrin with this type of asymmetric substitution is classified as a type III porphyrin.
    [Show full text]
  • Bilirubin Metabolism (Lecture 8)
    Bilirubin Metabolism (Lecture 8) Excretory function of bile Bile is a medium for excretion of many substances as bile pigments, cholesterol, many drugs, toxins and various organic substances as copper and zinc. These substances are then eliminated in the feces. One of these substances excreted in bile is the greenish yellow pigment bilirubin. This is a major end product of hemoglobin degradation. It’s highly soluble in all cell membranes & is also very toxic. Therefore, its excretion in the bile is one of the very important functions of the liver. FATE OF RED BLOOD CELLS Life span of RBCs in blood stream is 60-120 days. Senescent RBCs become too fragile to exist longer in the circulatory system, their cell membranes rupture and they are phagocytosed and/or lysed. Normally, lysis occurs extravascularly in the reticuloendothelial system subsequent to RBC phagocytosis. Lysis can also occur intravascularly (in blood stream). The hemoglobin is first split into globin & heme. The AA formed from breakdown of globin are stored in the body. Metabolism of bilirubin The heme ring is opened to give: 1. Free iron that is transported in the blood by transferrin and stored in the body as a reservoir for erythropoiesis. 2. Bile pigments: The 1st pigment is biliverdin but it is rapidly reduced by biliverdin reductase to free bilirubin which is gradually released into the plasma. The free bilirubin is hydrophobic, immediately combines with plasma proteins (mainly albumin and globulin) forming a water soluble compound called hemobilirubin (unconjugated bilirubin) which is rapidly transported to hepatocytes for further metabolism. Even when bound to albumin it’s called free bilirubin.
    [Show full text]
  • Biochemistry I Enzymes
    BIOCHEMISTRY I 3rd. Stage Lec. ENZYMES Biomedical Importance: Enzymes, which catalyze the biochemical reactions, are essential for life. They participate in the breakdown of nutrients to supply energy and chemical building blocks; the assembly of those building blocks into proteins, DNA, membranes, cells, and tissues; and the harnessing of energy to power cell motility, neural function, and muscle contraction. The vast majority of enzymes are proteins. Notable exceptions include ribosomal RNAs and a handful of RNA molecules imbued with endonuclease or nucleotide ligase activity known collectively as ribozymes. The ability to detect and to quantify the activity of specific enzymes in blood, other tissue fluids, or cell extracts provides information that complements the physician’s ability to diagnose and predict the prognosis of many diseases. Further medical applications include changes in the quantity or in the catalytic activity of key enzymes that can result from genetic defects, nutritional deficits, tissue damage, toxins, or infection by viral or bacterial pathogens (eg, Vibrio cholerae). Medical scientists address imbalances in enzyme activity by using pharmacologic agents to inhibit specific enzymes and are investigating gene therapy as a means to remedy deficits in enzyme level or function. In addition to serving as the catalysts for all metabolic processes, their impressive catalytic activity, substrate specificity, and stereospecificity enable enzymes to fulfill key roles in additional processes related to human health and well-being. Proteases and amylases augment the capacity of detergents to remove dirt and stains, and enzymes play important roles in producing or enhancing the nutrient value of food products for both humans and animals.
    [Show full text]
  • NEONATAL Hb, O2-TRANSPORT & JAUNDICE: OVERVIEW
    BILIRUBIN METABOLISM & JAUNDICE UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ Temple 1 Brief description of Hemoglobin (Hb) structure • Hemoglobin (Hb): Made up of 4-Subunits (Tetramer) held together by multiple non-covalent interactions; • Each subunit consist of: • Heme (Ferro-Protoporphyrin), • Globin protein; • Heme: Protoporphyrin IX and Ferrous ion (Fe2); • Globin protein folds around Heme group forming a protective Hydrophobic pocket; • Heme is the site of Oxygen binding; 2 • There are different types of Hemoglobin, with different subunits: • Foetal Hemoglobin (Hb F): 2 2 Two types of Adult Hemoglobin (Hb A): • Hb A1 represented as: 2 2 • It is the major (98%) form of Hb in adults; • Hb A2 represented as: 2 2 • It is the minor (2%) form of Hb in adults; 3 What are the major sources of Heme in humans? • RBC is major source of Heme in humans, • Life span of RBC is about 120 days, • Other sources of Heme include: • Myoglobin (Mb): Stores Oxygen in muscle cells, • Cytochromes: present in some enzymes, • Catalase: an enzyme, 4 What normally happens to RBC after 120 days? • RBC is destroyed mainly in Reticuloendothelial system (Extra-vascular system: Spleen and Liver); • Daily turnover of Hb is about 6 g/day; • Hb is broken down, • Globin protein is hydrolyzed to amino acids, • Protoporphyrin Ring in Heme is Hydrophobic, thus must be made soluble before it is excreted, • Ferrous ion is removed and stored in Iron pool, for reuse, • Protoporphyrin ring is metabolized
    [Show full text]
  • Baseline Levels of Endogenous Compounds in the Caucasian Population S
    Feasibility assessment of PBPK modelling for Endogenous Compounds: Baseline levels of endogenous compounds in the Caucasian population S. Neuhoff, H.E. Humphries, H. K. Crewe, Z. E. Barter, and K. Rowland-Yeo Simcyp Ltd (a Certara company), Blades Enterprise Centre, Sheffield, S2 4SU [email protected] BACKGROUND RESULTS (cont) RESULTS (cont) • There is increasing interest in the • Bilirubin and glucuronides 27-Hydroxycholesterol potential utility of Endogenous Cholesterol 1g/day A schematic of the formation and Compounds (EC’s) as biomarkers for CYP7A1 (liver) 500 mg/day CYP27A1 (many tissues) breakdown of bilirubin is shown in assessment of drug-induced enzyme 19 mg/day Figure 4. Total serum bilirubin (bilirubin 7α-Hydroxycholesterol level/activity changes of (a) CYP3A or CYP3A4 + bilirubin glucuronide), conjugated and Bile Acids (b) UGT1A1 following chronic dosing of 4-Hydroxycholesterol unconjugated plasma levels reflect the drug of interest. CYP27A1 (liver and extrahepatic) 24S-Hydroxycholesterol protein changes differently. • In July 2013, Consortium Members Pregnenolone were asked to identify a series of EC’s 4,27-Dihydroxycholesterol Macrophage CYP27A1 • Biliverdin reductase reduces Heme Hemeoxygenase for further evaluation, with a view to 4,24-Dihydroxycholesterol Biliverdin to unconjugated, water- Biliverdin 4,7α-Dihydroxycholesterol insoluble Bilirubin, which is Biliverdin reductase implementation within the Simcyp Bilirubin carried in blood bound to serum Unconjugated bilirubin Simulator. albumin complexed with albumin 3
    [Show full text]
  • Bilirubin PDF 12Days
    Bilirubin Physiology – WYNTKFTB • Bilirubin metabolism – Unconjugated – Conjugation – Excretion • Enterohepatic circulation • Implication of bilirubin metabolism – Urine – Stool • Understand the metabolic pathway as related to the disease state of JAUNDICE Don’t make me come up there and steal your google machines! BR - Alb Thank you. BG the Bilirubin an overview by howard sachs Slo-Motion Instant Replay… Heme oxygenase Biliverdin Reductase Heme oxygenase Biliverdin Reductase Bilirubin Albumin (unconjugated) …not water soluble… Unconjugated Bilirubin (‘Indirect’) Key points: • ‘Attached to albumin’: too big to pass through glomerular filtration barrier. • Intravascular: Hemoglobin ® urine • Unconjugated: not water soluble. How can we get too much unconjugated bilirubin in the serum? 1. Hemolysis • Elevated indirect bilirubin is used as a diagnostic marker (with ­ LDH, ¯ haptoglobin) 2. Conjugation defect: inherited (Gilbert’s, Crigler-Najjar) Multidrug resistance associated protein Bilirubin binds to cytosolic binding protein, glutathione s-transferase (GST) for transport to ER Conjugation of bilirubin is catalyzed by bilirubin-uridinediphosphate (UDP)- glucuronosyltransferase (UGT1A1). Product is bilirubin diglucuronide. UDPGA is the donor sugar Multidrug resistance Endoplasmic reticulum associated protein Bilirubin diglucuronide Conjugated (direct) Bilirubin binds to cytosolic binding protein, glutathione s-transferase (GST) for transport to ER Conjugation of bilirubin is catalyzed by bilirubin-uridinediphosphate (UDP)- glucuronosyltransferase
    [Show full text]
  • Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors
    Pharmaceutics 2011 , 3, 615-635; doi:10.3390/pharmaceutics3030615 OPEN ACCESS pharmaceutics ISSN 1999-4923 www.mdpi.com/journal/pharmaceutics Review Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors Toshihisa Ishikawa 1,*, Kenkichi Takahashi 2, Naokado Ikeda 2, Yoshinaga Kajimoto 2, Yuichiro Hagiya 3, Shun-ichiro Ogura 3, Shin-ichi Miyatake 2 and Toshihiko Kuroiwa 2 1 Omics Science Center, RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan 2 Department of Neurosurgery, Osaka Medical College, Osaka 569-8686, Japan 3 Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama 226-8501, Japan * Author to whom correspondence should be addressed: E-Mail: [email protected]; Tel.: +81-45-503-9222; Fax: +81-45-503-9216. Received: 19 July 2011; in revised form: 16 August 2011 / Accepted: 9 September 2011 / Published: 14 September 2011 Abstract: Photodynamic diagnosis (PDD) is a practical tool currently used in surgical operation of aggressive brain tumors, such as glioblastoma. PDD is achieved by a photon-induced physicochemical reaction which is induced by excitation of protoporphyrin IX (PpIX) exposed to light. Fluorescence-guided gross-total resection has recently been developed in PDD, where 5-aminolevulinic acid (ALA) or its ester is administered as the precursor of PpIX. ALA induces the accumulation of PpIX, a natural photo-sensitizer, in cancer cells. Recent studies provide evidence that adenosine triphosphate (ATP)-binding cassette (ABC) transporter ABCG2 plays a pivotal role in regulating the cellular accumulation of porphyrins in cancer cells and thereby affects the efficacy of PDD.
    [Show full text]
  • Bilirubin Secretion, Jaundice and Evaluation of Liver Function
    Bilirubin Secretion, Jaundice and Evaluation of Liver Function Howard J. Worman, M. D. Evaluation of Liver Disease and Hepatic Function History Physical Examination Laboratory Tests Sometimes Radiological/Nuclear Medicine Sometimes Liver Biopsy 1 Jaundice occurs as a result of excess bilirubin in the blood. It is a hallmark of liver disease but not always present in liver disease. Jaundice occurs when the liver fails to adequately secrete bilirubin from the blood into the bile. To understand how jaundice occurs, you must first understand bilirubin synthesis, metabolism and secretion. 2 Heme Oxygenase Schuller et al. Nature Structural Biology 6, 860 - 867 (1999) Bilivirdin Reductase Kikuchi et al. Nature Structural Biology 8, 221 - 225 (2001) 3 Bilirubin is frequently depicted as a linear tetrapyrrole. However, intramolecular hydrogen bonding fixes it in a rigid structure that blocks exposure of its polar groups to aqueous solvents, making it very insoluble in blood. 4 Bilirubin in Blood is Bound to Albumin: Uptake into Hepatocyte at Basolateral (Sinusoidal) Membrane Some OATP-C? bilirubin stored in cytosol bound to proteins Bilurubin UDP-glucuronosyltransferase is localized to the endo- plasmic reticulum; it catalyzes conjugation to a diglucuronide, making it more water soluble. A: Labeling of periphery of cell hepatocyte nucleus B: Labeling of ER with antibody to UDP-glucuronosyltransferase 5 Alternative RNA splicing of different first exons of UGT1 gives different isoforms with different substrate specificities, some for bilirubin and others
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2001/0034023 A1 Stanton, JR
    US 2001.0034O23A1. (19) United States (12) Patent Application Publication (10) Pub. No.: US 2001/0034023 A1 Stanton, JR. et al. (43) Pub. Date: Oct. 25, 2001 (54) GENE SEQUENCE VARIATIONS WITH Related U.S. Application Data UTILITY IN DETERMINING THE (63) Continuation-in-part of application No. 09/710,467, TREATMENT OF DISEASE, INGENES filed on Nov. 8, 2000, which is a continuation-in-part RELATING TO DRUG PROCESSING of application No. 09/696,482, filed on Oct. 24, 2000. Non-provisional of provisional application No. 60/131,334, filed on Apr. 26, 1999. Non-provisional (76) Inventors: Vincent P. Stanton JR., Belmont, MA of provisional application No. 60/139,440, filed on (US); Martin Zillmann, Shrewsbury, Jun. 15, 1999. MA (US) (30) Foreign Application Priority Data Correspondence Address: Jan. 20, 2000 (WO)........................... PCT/USOO/O1392 EDWARD O. KRUESSER BROBECK PHLEGER & HARRISON Publication Classification 12390 EL CAMINO REAL (51) Int. Cl. ............................. C12O 1/68; G06F 19/00 SAN DIEGO, CA 92130 (US) (52) U.S. Cl. ................................................... 435/6; 702/20 (57) ABSTRACT (21) Appl. No.: 09/733,000 Methods for identifying and utilizing variances in genes relating to efficacy and Safety of medical therapy and other aspects of medical therapy are described, including methods (22) Filed: Dec. 7, 2000 for Selecting an effective treatment. US 2001/0034023 A1 Oct. 25, 2001 GENE SEQUENCE WARIATIONS WITH UTILITY 0005 For some drugs, over 90% of the measurable IN DETERMINING THE TREATMENT OF interSubject variation in Selected pharmacokinetic param DISEASE, INGENES RELATING TO DRUG eters has been shown to be heritable. For a limited number PROCESSING of drugs, DNA sequence variances have been identified in Specific genes that are involved in drug action or metabo RELATED APPLICATIONS lism, and these variances have been shown to account for the 0001.
    [Show full text]
  • Inherited Disorders of Bilirubin Clearance N
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Hofstra Northwell Academic Works (Hofstra Northwell School of Medicine) Donald and Barbara Zucker School of Medicine Journal Articles Academic Works 2015 Inherited disorders of bilirubin clearance N. Memon B. I. Weinberger Zucker School of Medicine at Hofstra/Northwell T. Hegyi L. M. Aleksunes Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles Part of the Pediatrics Commons Recommended Citation Memon N, Weinberger B, Hegyi T, Aleksunes L. Inherited disorders of bilirubin clearance. 2015 Jan 01; 79(3):Article 2776 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/2776. Free full text article. This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [email protected]. HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pediatr Manuscript Author Res. Author manuscript; Manuscript Author available in PMC 2016 April 05. Published in final edited form as: Pediatr Res. 2016 March ; 79(3): 378–386. doi:10.1038/pr.2015.247. Inherited Disorders of Bilirubin Clearance Naureen Memon1,*, Barry I Weinberger2, Thomas Hegyi1, and Lauren M Aleksunes3 1Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA 2Department of Pediatrics, Cohen Children’s Medical Center of New York, New Hyde Park, NY, USA 3Department of Pharmacology and Toxicology, Rutgers University, Piscataway, NJ, USA Abstract Inherited disorders of hyperbilirubinemia may be caused by increased bilirubin production or decreased bilirubin clearance.
    [Show full text]
  • Novel Pharmacogenomic Markers of Irinotecan-Induced Severe Toxicity in Metastatic Colorectal Cancer Patients
    Novel pharmacogenomic markers of irinotecan-induced severe toxicity in metastatic colorectal cancer patients Thèse Siwen Sylvialin Chen Doctorat en sciences pharmaceutiques Philosophiae doctor (Ph.D.) Québec, Canada © Siwen Sylvialin Chen, 2015 ii Résumé L’irinotécan est un agent de chimiothérapie largement utilisé pour le traitement de tumeurs solides, particulièrement pour le cancer colorectal métastatique (mCRC). Fréquemment, le traitement par l’irinotécan conduit à la neutropénie et la diarrhée, des effets secondaires sévères qui peuvent limiter la poursuite du traitement et la qualité de vie des patients. Plusieurs études pharmacogénomiques ont évalué les risques associés à la chimiothérapie à base d’irinotécan, en particulier en lien avec le gène UGT1A, alors que peu d’études ont examiné l’impact des gènes codant pour des transporteurs. Par exemple, le marqueur UGT1A1*28 a été associé à une augmentation de 2 fois du risque de neutropénie, mais ce marqueur ne permet pas de prédire la toxicité gastrointestinale ou l’issue clinique. L’objectif de cette étude était de découvrir de nouveaux marqueurs génétiques associés au risque de toxicité induite par l’irinotécan, en utilisant une stratégie d’haplotype/SNP-étiquette permettant de maximiser la couverture des loci génétiques ciblés. Nous avons analysé les associations génétiques des loci UGT1 et sept gènes codants pour des transporteurs ABC impliqués dans la pharmacocinétique de l’irinotécan, soient ABCB1, ABCC1, ABCC2, ABCC5, ABCG1, ABCG2 ainsi que SLCO1B1. Les profils de 167 patients canadiens atteints de mCRC sous traitement FOLFIRI (à base d’irinotécan) ont été examinés et les marqueurs significatifs ont par la suite été validés dans une cohorte indépendante de 250 patients italiens.
    [Show full text]